Learn more about the benefits of early sodium-glucose cotransporter 2 inhibitor initiation for heart failure patients, both in the acute and chronic settings, in improving CV and hospitalization outcomes and mitigating the damage of upstream cardio-renal-metabolic (CRM) risk factors.